Amicus Therapeutics Inc (FOLD) FinancialsFOLDFinancialAmicus Therapeutics Inc

Evaluating the bottom line, Amicus Therapeutics Inc maintains a gross margin of 84.64%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 8.61%, while the net margin is 0.91%. These profitability ratios, combined with a Return on Equity (ROE) of -11.58%, provide a clear picture of how effectively FOLD converts its operational activities into shareholder value.

In the context of the broader market, FOLD competes directly with industry leaders such as LGND and LEGN. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, FOLD's gross margin of 84.64% stands against LGND's 82.24% and LEGN's 64.54%. Such benchmarking helps identify whether Amicus Therapeutics Inc is trading at a premium or discount relative to its financial performance.

In 2025/Q4, revenue increased by 23.72% YoY to $185.21M, but net income dropped significantly by -88.53% YoY to $1.69M. EPS also fell by -80.00% YoY to $0.01, and gross margin declined by -4.61% YoY to 84.64%. The financial performance indicates growth in revenue but significant profitability challenges.